Paloma Partners’s iRadimed IRMD Stock Holding History

Paloma Partners’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-14,700	Closed	-$126K	–	2254
2017 Q2	$126K	Buy	+14,700	New	+$125K	﹤0.01%	2057

Other funds holding IRMD

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return

SIM

Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Paloma Partners's IRMD Position: Q3 2017 in Review

Paloma Partners sold out of iRadimed (IRMD) in Q3 2017, closing a stake of 14,700 shares — an estimated $126K sold.

Paloma Partners first reported a position in IRMD in Q2 2017 and held it in 1 quarter. The position peaked at $126K in Q2 2017. 29 funds tracked by Wall St. Rank hold IRMD as of Q3 2017.

Paloma Partners reported no remaining iRadimed position as of Q3 2017 after selling out during the quarter.
Paloma Partners sold 14,700 iRadimed shares in Q3 2017, an estimated $126K.
Paloma Partners first reported a position in iRadimed in Q2 2017 and held it in 1 quarter.
Paloma Partners's iRadimed position peaked at $126K in Q2 2017.
29 funds tracked by Wall St. Rank held iRadimed as of Q3 2017.

Based on Paloma Partners's 13F filing for Q3 2017, filed 14 Nov 2017.